Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review.
OBJECTIVE
The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.


METHODS
A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease's patients treated for different solid tumors.


RESULTS
Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.


CONCLUSIONS
A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
76 Vassilissis Sofias Avenue, 115 28, Athens, Greece. martolia@med.uoa.gr.
Maria
M
Tolia
Anna
A
Zygogianni
John R
JR
Kouvaris
Nikolaos
N
Tsoukalas
Ioannis
I
Kokakis
George
G
Kyrgias
Kyriaki
K
Mystakidou
Vasileios
V
Kouloulias
D002986:Clinical Trials as Topic; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D009369:Neoplasms / Q000150:complications* / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology*